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Ubiquitination plays a pivotal role in several cellular processes and is critical for protein
degradation and signaling. E3 ubiquitin ligases are the matchmakers in the ubiquitination
cascade, responsible for substrate recognition. In order to achieve selectivity and
specificity on their substrates, HECT E3 enzymes are tightly regulated and exert their
function in a spatially and temporally controlled fashion in the cells. These characteristics
made HECT E3s intriguing targets in drug discovery in the context of cancer biology.
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HECT E3 LIGASES
Post-translational modification of proteins by the addition of a ubiquitin (Ub) moiety can induce
alteration in protein stability, function, activity, localization and interaction (Komander and Rape,
2012). This tightly regulated process (reviewed in Oh et al., 2018) requires the sequential action of
a cascade of three enzymes: the Ub-activating enzyme (E1), Ub-conjugating enzymes (E2s), and
Ub ligases (E3s). E3 ligases are the matchmakers of the enzymatic cascade, as they are capable of
conferring a high degree of specificity and selectivity toward target substrates in cells. The human
proteome codifies for more than 600 E3s (Li et al., 2008; Berndsen and Wolberger, 2014) that
can be divided into three classes: the largest class is the RING (Really Interesting New Gene/U-
box)-type E3s with about 600 members (reviewed in Metzger et al., 2014), followed by the HECT
(Homologous to E6AP C-Terminus)-type E3s with about 28 members (reviewed in Rotin and
Kumar, 2009 and Sluimer and Distel, 2018) and the RBR (RING between RING)-type E3s with
about 14 members (reviewed in Dove and Klevit, 2017 and Reiter and Klevit, 2018). Whereas the
RING E3 ligases function as allosteric activators of the E2 and scaffolds that bring the latter in close
proximity to the substrate, the HECT and RBR E3 ligases catalyze substrate ubiquitination in a two-
step reaction: in the first step, they accept the activated Ub from the E2 in a transthiolation reaction
on their catalytic cysteine, and in the second step, the Ub moiety is transferred to a lysine on the
target substrate.
In this review, we focus on the HECT-containing E3 ligases. Invariably at their C-terminus,
all HECT E3s present the catalytic HECT domain, composed of a bulkier N-terminal lobe (N-lobe)
that contains the E2 binding domain, and a C-terminal lobe (C-lobe) carrying the catalytic cysteine.
The two lobes are connected by a flexible hinge region that allows the C-lobe to move around in
order to facilitate the Ub transfer from the E2 to the E3 (Huang et al., 1999; Verdecia et al., 2003;
Kamadurai et al., 2009).
According to the domain organization present in the N-terminal part of the proteins, the
HECT E3s can be subdivided into three main families (Table 1; Rotin and Kumar, 2009;
Scheffner and Kumar, 2014; Sluimer and Distel, 2018). The best characterized family is the
NEDD4 family, consisting of nine human members: ITCH, SMURF1, SMURF2, WWP1, WWP2,
NEDD4, NEDD4-2, HECW1, and HECW2. The NEDD4 members share similar domain structure
and consist of a membrane/lipid-binding C2 domain, two to four WW domains for substrate
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recognition and a C-terminal HECT domain (Fajner et al., 2017).
The second class, the HERC family, is characterized by one
or more regulators of chromatin condensation 1 (RCC)-like
domains (RLD), which serve as a guanine nucleotide exchange
factor (GEF) for the small GTPase in membrane trafficking
processes (Sanchez-Tena et al., 2016). This family consists of
six members that can be subdivided into four ‘small’ and two
‘large’ HERCs, where the latter, HERC1 and HERC2, are the
largest HECT E3s with about 5000 residues. The remaining
13 HECTs do not share specific domains at the N-terminus
and, for this reason, are classified as “other” HECT ligases
(Scheffner and Kumar, 2014).
REGULATION OF HECT E3 LIGASE
ACTIVITY
The activity of HECT E3s is tightly regulated in terms of chain
specificity (mono- or poly-ubiquitination and Ub chain linkage),
interaction with the E2 and recognition of the substrate.
TABLE 1 | Overview of the human HECT E3 ligase subfamilies with the respective
members, including their domain organization.
Subfamily Domains Members
NEDD4 C2, WW (4x), HECT NEDD4, NEDD4-2, ITCH,
WWP1, WWP2
C2, WW (3x), HECT SMURF2
C2, WW (2x), HECT SMURF1, HECW1, HECW2
HERC RLD (2x), SPRY, WD40, HECT HERC1
RLD (3x), Cytb5, MIB, ZnF,
DOC, HECT
HERC2
RLD, HECT HERC3, HERC4, HERC5,
HERC6
“Other” HECT AZUL, HECT E6AP
ARM, UBA, WWE, BH3, UBM,
HECT
HUWE1
ANK, HECT HACE1
ARM (2x), WWE, HECT TRIP12
UBA, ZnF, PABC, HECT UBR5
IQ, HECT UBE3B, UBE3C
ANK, SUN, MIB, HECT HECTD1
HECT HECTD2, HECTD4
DOC, HECT HECTD3
PHD/RING, HECT G2E3
Filamin, HECT AREL1
Protein domains were predicted by the InterPro server (Finn et al., 2017). HECT
E3 ligases are grouped into three subfamilies, NEDD4, HERC, and “other”
HECT E3 ligases based on their domain architecture N-terminal to the HECT
domain. Domain abbreviations used are as follows: C2, C2 domain (Ca2+-
binding domain); WW, WW domain; HECT, homologous to E6AP C-terminus; RLD,
Regulator of Chromosome Condensation 1 repeat-like domain; SPRY, B30.2/SPRY
domain; WD40, W-D repeat domain; Cytb5, cytochrome b5-like heme/steroid-
binding domain; DOC, APC10/DOC domain; MIB, MIB-HERC2 domain; ZnF, Zinc
finger domain; AZUL, amino-terminal Zn-binding domain of UBE3A ligase; ARM,
Armadillo repeat-containing domain; UBA, ubiquitin-associated domain; WWE,
WWE domain; BH3, Bcl-2 homology 3 domain; UBM, ubiquitin-binding motif;
ANK, Ankyrin repeat-containing domain; PABC, polyadenylate-binding protein
C-terminal domain; IQ, IQ motif/EF-hand binding site; SUN, SAD1/UNC domain;
PHD, PHD-type zinc finger; Filamin, filamin/ABP280 repeat-like domain.
The ability to build linkage-specific poly-Ub chains appears to
be an intrinsic feature of the HECT enzymes, as they are able to
generate distinct Ub chains regardless of the paired E2 enzymes.
NEDD4 family members primarily synthesize K63 chains (Kim
and Huibregtse, 2009; Maspero et al., 2013; Kristariyanto et al.,
2015), while E6AP is a K48-specific enzyme (Wang and Pickart,
2005; Kim and Huibregtse, 2009) and HUWE1 generates K6-,
K11-, and K48- linked poly-Ub chains (Jackl et al., 2018). In
most of the cases, the detailed mechanism through which they
assemble specific poly-Ub chains remains unknown. In the case
of NEDD4, the presence of a non-covalent Ub-binding site, called
the Ub exosite, in the N-lobe appears to be required for enzyme
processivity, possibly by stabilizing and orienting the distal end of
growing Ub chains on the substrate (Maspero et al., 2011, 2013).
Precise control of E3 ligase activity is needed to ensure that
their functions are restricted until required. Several HECT E3s are
kept in a catalytically inactive state by intramolecular interactions
between the N-terminal region (either the C2 or the linker
region between the WW domains) and the C-terminal HECT
domain (Wiesner et al., 2007; Mari et al., 2014; Riling et al.,
2015; Chen et al., 2017; Zhu et al., 2017). For other E3s, such
as E6AP and HUWE1, the mechanism is different but always
requires intermolecular interactions. The crystal structure of the
free HECT domain of E6AP suggests that it forms a trimer
(Huang et al., 1999) and that the trimeric state activates the E3
ligase (Ronchi et al., 2014). In contrast, the C-terminal region
of HUWE1 is maintained in an inactive conformation by homo-
dimerization that occurs at the HECT domain. The engagement
of the dimerization region by an activation segment located at
the N-terminal of the protein seems to relieve this inhibitory
mechanism (Sander et al., 2017).
A third level of regulation is represented by adaptor proteins
that can modulate both the E2–E3 interaction and the interaction
with the substrate. An example of the former is represented by
SMAD7. SMURF1 and SMURF2 have low binding affinities for
the E2-conjugating enzyme UbcH7, providing a point of control
for regulating the Ub ligase activity through the action of auxiliary
proteins. Indeed, SMAD7, functioning as a bridge between the
E2 and E3, stabilizes an active complex and promotes, thus, the
ligase activity (Ogunjimi et al., 2005). In other cases, adaptor
proteins may regulate the E3 ligase by promoting its engagement
with the substrate. The most famous example is represented by
the adaptor protein E6 that binds to a LxxLL motif of the E6AP
HECT ligase and forms, together with E6AP, a binding surface
for the p53 protein. Consequently, p53 becomes K48-poly-
ubiquitinated and degraded by the 26S proteasome (Huibregtse
et al., 1993; Martinez-Zapien et al., 2016). NEDD4 family E3s
usually recruit substrates via the WW domains that serve as direct
binding sites for PPxY motifs present on the targets (Persaud
et al., 2009). In this case, cooperation with auxiliary proteins
confers the ability to cope with a larger number of substrates.
Indeed, in the last decade, proteins such as ARTs in yeast and
ARRDCs in mammals were found to modulate the ubiquitination
of PY-negative substrates (Lin et al., 2008; Polo and Di Fiore,
2008; Mund and Pelham, 2009; Han et al., 2013). Other adaptor
proteins which contribute to NEDD4 family members regulation
are NDFIP1 and NDFIP2, transmembrane proteins that localize
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to Golgi, endosomes, and multivesicular bodies (Harvey et al.,
2002; Shearwin-Whyatt et al., 2006). Through their cytoplasmic
PY motifs they allow the association of NEDD4 family members
to their specific substrates [e.g., DMT1 (Foot et al., 2008),
ENaC (Konstas et al., 2002) the water channel AQP2 (Trimpert
et al., 2017)] and directly modulate the activity of these E3s
(Mund and Pelham, 2009, 2010).
Notably, HECTs themselves can function as adaptors for other
conjugating enzymes as in the case of HERC2 whose binding to
the N-terminal domain of E6AP increases the catalytic activity of
E6AP (Kuhnle et al., 2011).
Finally, the catalytic activity of the HECT enzymes is
often spatially and temporally regulated by post-translational
modifications. Activating modifications can contribute to the
release of auto-inhibiting conformational states of the E3s.
For example, the phosphorylation of ITCH on the three
residues of the proline-rich region releases the auto-inhibitory
state generated by the binding of the C2 and the first WW
domain to the HECT domain (Gallagher et al., 2006). Likewise,
FGFR and EGFR activate NEDD4 by inducing a Src-dependent
phosphorylation of specific tyrosine residues in the C2 and
HECT domains, opening thus the closed conformation (Persaud
et al., 2014); a mechanism that seems to be in place also for
NEDD4-2 (Grimsey et al., 2018). With an opposite behavior,
phosphorylation of a specific residue in the HECT domain of
E6AP by the kinase c-Abl disrupts the trimeric state and therefore
inhibits the ligase (Chan et al., 2013).
HECT E3 LIGASES AND THEIR
UNDEFINED ROLE IN TUMORIGENESIS
Ubiquitin ligases regulate a wide range of cellular processes and
are involved in many human pathologies. Abnormal expression
or dysfunction of HECT E3s have been shown in many different
cancers. The current knowledge often suggests a dual role for
these ligases in tumorigenesis, which might depend on the tissue
context and/or additional events that affect their activity. Here,
we will review the recent literature on E6AP, NEDD4, and
HUWE1, and highlight excellent reviews for additional reading
(Bernassola et al., 2008; Rotin and Kumar, 2009; Scheffner and
Kumar, 2014; Zou et al., 2015; Wang et al., 2017; Kao et al., 2018).
The classical example of an HECT associated with cancer is
E6AP. Since its discovery in 1993, it was evident that E6AP drives
human papilloma virus (HPV)-induced cervical carcinogenesis,
exerting its activity toward the tumor suppressor p53 through its
association with the viral protein E6. E6 is an adaptor protein of
the HPV and it is capable of binding to the N-terminal of EA6P
and the DNA-binding domain of p53 (Huibregtse et al., 1993;
Scheffner et al., 1993; Beaudenon and Huibregtse, 2008), acting as
an allosteric activator of E6AP (Mortensen et al., 2015), similarly
to HERC2 that binds to the same region (Kuhnle et al., 2011). In
addition to HPV-induced cancer, E6AP drives cancer progression
in B-cell lymphoma where it degrades PML, allowing the tumor
cells to bypass PML-induced senescence (Wolyniec et al., 2012).
While E6AP appears to have a pro-oncogenic function, a few
papers support a tumor-suppressive function for E6AP in breast
and prostate cancers (Srinivasan and Nawaz, 2011; Levav-Cohen
et al., 2012; Ramamoorthy et al., 2012; Mansour et al., 2016)
and in non-small cell lung cancer where depletion of E6AP
contributes to a decreased expression of the INK4/ARF locus
(Gamell et al., 2017).
NEDD4 and NEDD4-2 E3s are instead modulators of
endocytosis of several membrane proteins such as growth factor
receptors [EGFR (Katz et al., 2002) and IGFR (Vecchione et al.,
2003; Cao et al., 2008)] and ion channels [ENaC (Staub et al.,
1996; Harvey et al., 2001), Navs (Fotia et al., 2004), and KCNQs
(Ekberg et al., 2007; Jespersen et al., 2007)] therefore they are
important players in the maintenance of cellular homeostasis.
Mutations at the C-terminal of ENaC subunits that abrogate the
interaction with NEDD4-2 are the cause of Liddle’s syndrome, an
autosomal dominant disorder with severe sodium retention and
hypertension (Staub et al., 1996).
Overexpression of NEDD4 has been reported in several
cancer types and downregulation of NEDD4 appears to reduce
proliferation, migration and invasion of cancer cells (reviewed in
Zou et al., 2015). The relevance of NEDD4 in the tumorigenic
process was initially associated with the identification of the
tumor suppressor PTEN as a NEDD4 substrate (Trotman et al.,
2007; Wang et al., 2007; Kim et al., 2008; Amodio et al.,
2010). Later observations linked RAS activation to NEDD4
overexpression and subsequent PTEN degradation in human
colorectal cancer (Zeng et al., 2014). However, studies conducted
in NEDD4 knock out (KO) mice showed that PTEN stability was
not affected by the E3 ligase deficiency (Fouladkou et al., 2008),
while others showed that overexpression of NEDD4 in colorectal
cancers promotes cancer cell growth independently of PTEN and
PI3K/AKT signaling, arguing that NEDD4-mediated regulation
of PTEN is microenvironment and/or cell-type specific, and that
other yet-unknown substrates are implicated in the process (Eide
et al., 2013). While this latter remains an intriguing hypothesis,
it is interesting to note that in vivo NEDD4 is reported to
degrade many of its substrates, while in vitro its activity is
clearly K63-specific (Kim and Huibregtse, 2009; Maspero et al.,
2013). A possible explanation for this behavior resides in the
involvement of adaptor proteins that could influence the specific
type of Ub chains catalyzed by E3s [e.g., NUMB (Shao et al.,
2017)] or deubiquitinases that may edit the Ub chains.
A last case study is represented by HUWE1, which is
also frequently overexpressed in tumors (Chen et al., 2005;
Confalonieri et al., 2009; Myant et al., 2017). Again, HUWE1 has
been associated with both pro-oncogenic and tumor suppressor
functions since it is responsible for K48-mediated degradation
of a great variety of substrates ranging from the oncoprotein
MYC (Zhao et al., 2008; Inoue et al., 2013; Myant et al., 2017)
to the anti-apoptotic protein MCL1, (Zhong et al., 2005) to the
tumor suppressor p53 (Chen et al., 2005) and BRCA1 (Wang
et al., 2014). Particularly controversial is the role of HUWE1
in the regulation of MYC. On the one hand, HUWE1 is able
to enhance tumor cell proliferation by K63-poly ubiquitination
and activation of the transcription regulator MYC (Adhikary
et al., 2005), on the other hand, depletion (Inoue et al., 2013)
or mutation (Myant et al., 2017) of HUWE1 lead to increased
MYC levels, thereby promoting skin and colon tumorigenesis.
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Clearly, a precise understanding of HUWE1 function in the
various cancers relies heavily on the identification of its direct
substrates and the type of Ub modification occurring to them.
TARGET SITES AND SPECIFICITY OF
HECT E3 LIGASE INHIBITORS
As previously described, the regulatory mechanisms of HECT E3s
are quite diverse and, therefore, provide a promising opportunity
for drug discovery (Chen et al., 2018). Based on the actual
knowledge, we can imagine different ways to inhibit their activity,
namely: (i) by blocking the binding of the E2 enzymes or adaptor
proteins; (ii) by tackling the catalytic cysteine of the enzymes; (iii)
by targeting specific regulatory surfaces such as the Ub exosite;
(iv) by impairing substrate recognition; and (v) by modulating
the oligomeric state (Figure 1).
Molecules that block the HECT-E2 binding were found by
Mund et al. (2014). By using a phage library, the authors isolated
and modified bicyclic peptides that specifically bind to the
HECT domains of SMURF2, NEDD4-1, WWP1, and HUWE1,
competing with the E2 binding. Further improvement of the most
promising peptide generated Heclin (HECT ligase inhibitor), a
reversible inhibitor with a low micromolar affinity that, however,
did not inhibit the E2 binding of the HECTs but rather caused a
conformational change that renders their catalytic cysteine more
susceptible to oxidation.
With the idea of identifying covalent modifiers of the catalytic
cysteine of NEDD4, Kathman et al. (2015) found compounds
that selectively react with a non-catalytic cysteine present
in the Ub exosite of NEDD4 and NEDD4-2. Interestingly,
no inhibition was observed for the NEDD4 family member
WWP1 that also contains a cysteine in close proximity to
the one seen in NEDD4, or for E6AP that does not contain
FIGURE 1 | Predicted inhibitory targets for HECT E3s activity. Surface representations of known crystal structures of HECT E3s. In circles are highlighted the
possible binding sites for small molecules. (A) Blocking the E2 binding: HECTNEDD4−2 in complex with Ub (gold)-loaded E2 (red; PDB 3JVZ). (B) Inhibition of the
catalytic cysteine: Ub (UbD, gold)-loaded HECTNEDD4 complex; PDB 4BBN. (C) Blocking the Ub exosite: HECTNEDD4 in complex with Ub bound to the exosite (UbE,
yellow; PDB 4BBN). (D) Inhibition of the oligomerization: HECTE6AP trimeric complex (1D5F). C-lobes and N-lobes are depicted in green and blue, respectively.
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a cysteine in this region (Kathman et al., 2015). Another
compound that may bind to the Ub exosite of the HECT
domain is I3C (1H-indol-3-yl-carbinol), a phytochemical found
in cruciferous vegetables that has an antiproliferative effect in
cancers (Ahmad et al., 2010). I3C was found to interact with
NEDD4 in vitro at micromolar concentrations (Adhikary et al.,
2005). Through in silico binding simulations between I3C and
the NEDD4 crystal structure, I3C was predicted to bind to the
hydrophobic pocket of the N-lobe near the Ub exosite. In a
follow-up study, Quirit et al. (2017) overcame the low binding
affinity of I3C by screening a small library of N-benzyl or
N-phenyl I3C analogs and identified 1-benzyl-indole-3-carbinol
(1-benzyl-I3C) as a more potent inhibitor. However, the binding
mode and the specificity of this compound has not been
experimentally validated.
A recent approach suggests the use of specific Ub mutants
identified by phage display (Ub variant, UbV) to modulate HECT
catalysis (Zhang et al., 2016). The screen performed against
19 of the 28 human HECT enzymes lead to the identification
of variants that are capable to bind the N-lobe exosite but
also the N-lobe surface involved in the interaction with the
E2 (Zhang et al., 2016). Binding of these variants promote
inhibition or activation depending on the E3 tested and the type
of modifications present in the UbV underlying the complexity
of the catalytic mechanism in place. While a generalization of the
process is impossible, these reagents appear to be interesting tools
for further studies.
A few molecules have been found to inhibit the HECTs,
impairing substrate binding. An in silico screening of the
hydrophobic pocket of the WW domains of SMURF1 led to
the identification of compounds that possess features similar
to the PPXY motif. These compounds bind the ligase and
block SMAD1 ubiquitination, possibly disrupting the WW
domain:SMAD1 interaction (Okada et al., 2009; Kato et al., 2011;
Cao et al., 2014). However, affinity, binding mode and selectivity
remain to be tested.
For many small molecules and inhibitors, the binding sites,
the mechanism or the specificity have not been determined. By
a high-throughput screening of small molecules, Eilers and co-
workers identified two compounds that selectively inhibit the
enzyme activity of HUWE1, as seen by a reduced substrate
ubiquitination. Both compounds were found to inhibit the ligase
activity with IC50 values in the low micromolar range, leaving
NEDD4 family members or the E1 and E2 enzymes unaffected.
The compounds reduced the growth of colorectal cancer cells,
but not that of HUWE1-depleted or normal epithelial cells of
the colon (Peter et al., 2014). However, how these compounds
work on HUWE1 remains unknown (Peter et al., 2014). With
a similar approach, Rossi and co-workers identified several
putative ITCH inhibitors, including Clomipramine, an FDA-
approved drug that is used in the clinic to treat psychiatric
disorders. Clomipramine and its analogs specifically block the
HECT catalytic activity of the NEDD4 family member ITCH
but not that of the RING ligase Ring1B (Rossi et al., 2014). The
authors clarified the mode of action of this class of drugs, showing
that it specifically inhibits the transthioesterification reaction (the
transfer of Ub from the E2 to the HECT domain), implying
some common features at the level of the HECT members
(Rossi et al., 2014).
CONCLUDING REMARKS
Although tackling the ubiquitination system rather than the
proteasome seems to be a promising avenue for therapeutic
drug discovery, targeting HECT E3s to manipulate their activity
is challenging for several reasons. First of all, we still lack
the complete picture of their ubiquitome and their mechanism
of action. Which substrates do HECT E3s ubiquitinate? What
impact does ubiquitination have on their function proteolytic
or non-proteolytic? How are these substrates recognized and
how is their ubiquitination regulated in time and space and
in different cellular conditions? What are the mechanisms the
different HECT E3s apply to ubiquitinate their targets? So far,
we only have a few answers for a small number of ligases
and substrates due to the fact that ubiquitination is a dynamic
and highly regulated process, and that the interaction with
substrates is often transient with a low binding affinity. Besides
the PPxY motif that is recognized by the WW domains of
NEDD4 family members, no other substrate binding motif is
known. An additional challenge is represented by redundancy.
While E3s target multiple substrates, a specific substrate may be
modulated by several E3s, depending also on the cell context.
The high conservation of the HECT domain within the HECT
family makes it a difficult target for which to develop specific
inhibitory compounds. Finally, most of the HECTs act as both
tumor suppressors and oncogenes, and more information is
needed in order to find specific and effective compounds. Thus,
acquiring more insights into the structural composition and the
ubiquitination mechanism used by the different HECT E3s is
of paramount importance in order to open new avenues for
therapeutic interventions.
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